ANSTO Gets $5 Million Funding from Federal Government

The recent allocation of $5 million AUD to develop Lutetium 177 at the Australian Nuclear Science & Technology Organisation (ANSTO) facilities at Lucas Heights (NSW) has been a collaboration between Dr Adi Paterson (CEO ANSTO), Jane Langford (ANSTO), Dr John Leyden (UF) and expert Australian Nuclear Medicine Physicians – Prof Turner, Prof Hicks et al.

Hopefully this will lead to medical grade Lutetium being produced locally which may be available for use in Australian Hospitals as early as 2014.

I would encourage every NET patient to email Dr Paterson (www.ansto.gov.au) and Senator Chris Evans (minister.evans@innovation.gov.au) and thank them for showing such vision and commitment in fostering this technology.

Unfortunately this money DOES NOT guarantee Australian NET patients access to "lutate" for treatment – this is reliant on funding from Federal and State Health budgets – of which there is none. This is a battle which we are still fighting and will need your help with soon. Watch this space, but in the meantime please put pen to paper.

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

Bringing Together Experts to Improve NET Patient Care: NECA at the 5th NET Preceptorship

NECA at ENETS 2025: Advancing NET Care on the Global Stage

The Australian Cancer Plan

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness

Walk, run, or ride this March4NETs!

For its third year, March4NETs will run throughout March 2026.

Get involved and support the 31,000 Australians living with neuroendocrine cancer.